[Selected aspects of diagnosis and treatment of prostatic cancer].

Prostatic cancer is one of the most frequent malignant tumours in men. The chronic course of the disease and the opportunity of selecting of one of many available treatment methods make possible adjustment of the management to the individual problems of the patient. This leads, however, to various difficulties connected with the selection of optimal management in various clinical situations.

CA-50 serum level in patients with prostate cancer.

CA-50 antigen is considered to be a generalized carcinoma-associated antigen. CA-50 serum levels were measured by solid phase radioimmunoassay using a specific monoclonal antibody. Sera of 49 patients with prostatic cancer of different clinical stages, 43 patients suffering from BPH, and 28 healthy males were tested.

Serum tissue polypeptide antigen (TPA) and prostatic acid phosphatase (PAP) in patients with prostatic cancer.

Concurrent measurements of serum TPA and PAP concentrations by double antibody radioimmunoassays were done in 49 patients with prostatic cancer in different clinical stages. The reference group comprised patients suffering from BPH. Positive TPA was found in 32.